Form 4: Halozyme Therapeutics Executive Exercises Stock Options, Sells Shares for Tax Obligations
SEC Form 4 Filing
Michael J. LaBarre, SVP and Chief Technical Officer of Halozyme Therapeutics, exercised stock options and sold shares to cover tax withholding obligations.
Summary
- Michael J. LaBarre, SVP and Chief Technical Officer of Halozyme Therapeutics, exercised stock options and performance stock units on February 15 and 16, 2025.
- He acquired a total of 34,652 shares of common stock through these exercises.
- Simultaneously, he disposed of shares to cover tax withholding obligations, with prices at $58.29 per share.
- The total number of shares disposed of for tax obligations was 15,292.
- Following these transactions, LaBarre directly owns 193,116 shares of Halozyme Therapeutics common stock.
- He also owns 8,526 restricted stock units.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports routine transactions related to executive compensation. There is no indication of positive or negative sentiment towards the company's performance or future prospects.
Industry Context
This filing is a routine disclosure of insider transactions, which are common for executives who receive stock options and restricted stock units as part of their compensation. These transactions do not necessarily reflect a change in the executive's confidence in the company's future prospects.
Comparison to Industry Standards
- Stock option and RSU grants are a standard component of executive compensation packages in the biotechnology industry, used to align management's interests with those of shareholders.
- The vesting schedules and exercise prices of these options are typically benchmarked against peer companies to ensure competitiveness.
- Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize similar equity-based compensation strategies for their executives.
Stakeholder Impact
- The transactions have a minimal impact on shareholders as they are related to routine executive compensation and tax obligations.
- The transactions do not directly affect employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 02/15/2025 | Date of earliest transaction: Exercise of stock options and disposition of shares for tax obligations. |
| 02/16/2025 | Exercise of performance stock units and disposition of shares for tax obligations. |
| 02/18/2025 | Date of signature for the Form 4 filing. |
Keywords
Form 4, Halozyme Therapeutics, Stock Options, Insider Trading, Michael J. LaBarre, Executive Compensation, Equity Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.